Mark William Smith

Newmarket Investments Plc provides investment services. It operates as a bloodstock agent trading through its subsidiary British Bloodstock Agency Plc and an equestrian insurance agent, trading through its subsidiary, BBA Insurance Services Ltd. The company was founded on November 24, 1911 and is headquartered in London, the United Kingdom.

Klareco Communications Pte Ltd. provides public relations consultancy services. The private company is based in Singapore, Singapore. The Singaporean company was founded by Ang Shih-Huei, Mark Worthington. Ang Shih-Huei has been the CEO since incorporation.

Part of Reuben Brothers SA, Northern Races Ltd. is a holding British company that operates racecourses through its subsidiaries. The company is based in London, UK.

Racing Welfare is a registered charity supporting the workforce of British horseracing. It offers professional guidance and practical help for the well-being of racing. The company was founded in 2000 and is headquartered in Newmarket, the United Kingdom.

Epilepsy Society is a charity organization that aims to transform the lives of people with epilepsy through world-leading research, advocacy, and care. The non-profit company is based in Buckinghamshire, UK. The British company offers courses to individuals who want to develop their understanding of therapeutic drug monitoring, which is a specialized area of clinical chemistry that measures drug levels in the blood. The society recognizes that everyone is different and provides care to ensure that every resident enjoys life to the fullest. The company's vision is to provide a full life for everyone affected by epilepsy. The company was founded in 1892, and Clare Pelham has been the CEO of the company since 2016.

Part of Chime Communications Ltd., Bell Pottinger Corporate & Financial Ltd. provides financial media relations services. The company is based in London, UK.

The Foundation for Liver Research, founded in 1974, conducts research on liver diseases and aims to use multi-omic biological data for diagnostics, management stratification, and therapeutic design. The non-profit company is based in London, UK. The British company's research includes susceptibility to bacterial infection in liver failure patients, mechanisms of neutrophil dysfunction, and hydrogen sulphide as a novel therapy. The company also focuses on in silico models and primary liver cancer.